New biopharma investing models emerge

04/9/2012 | Xconomy

As venture capital contracts, novel investment groups are emerging that include big drugmakers, governments, health care systems and patient advocacy groups, as highlighted in a recent report from Burrill & Co. One example is the Cystic Fibrosis Foundation's partnership with Aurora Biosciences and Vertex Pharmaceuticals, which yielded an innovative drug. But collaborations between for-profit corporations, governments and patient advocates are subject to competing priorities and ethical questions that must be addressed at the outset, writes Luke Timmerman.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations